CN116064767A - LncRNA marker related to osteoarthritis and application thereof - Google Patents

LncRNA marker related to osteoarthritis and application thereof Download PDF

Info

Publication number
CN116064767A
CN116064767A CN202211009871.0A CN202211009871A CN116064767A CN 116064767 A CN116064767 A CN 116064767A CN 202211009871 A CN202211009871 A CN 202211009871A CN 116064767 A CN116064767 A CN 116064767A
Authority
CN
China
Prior art keywords
hoxc
osteoarthritis
cell
chondrocytes
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202211009871.0A
Other languages
Chinese (zh)
Other versions
CN116064767B (en
Inventor
陈璐璐
王婵
苗登顺
王懿涵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Medical University
Original Assignee
Nanjing Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Medical University filed Critical Nanjing Medical University
Priority to CN202211009871.0A priority Critical patent/CN116064767B/en
Publication of CN116064767A publication Critical patent/CN116064767A/en
Application granted granted Critical
Publication of CN116064767B publication Critical patent/CN116064767B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention belongs to the fields of diagnosis, treatment and prognosis detection of osteoarthritis, and particularly discloses an LncRNA marker related to osteoarthritis and application thereof. The gene sequence of the LncRNA marker HOXC-AS3 is shown AS SEQ NO.3, and the primer for amplifying the LncRNA marker HOXC-AS3 is HOXC-AS3-F:5'-GTGGAGTAACAGCGCCATCT-3'; HOXC-AS3-R:5'-CGGGTTTTGTTGCGTCTTGT-3'. Studies have shown that reduced LncRNA HOXC-AS3 expression levels can be used AS biomarkers for diagnosis, treatment and prognosis of osteoarthritis.

Description

LncRNA marker related to osteoarthritis and application thereof
Technical Field
The invention belongs to the fields of diagnosis, treatment and prognosis detection of osteoarthritis, and relates to an osteoarthritis LncRNA marker and application thereof.
Background
Osteoarthritis (OA) is a chronic progressive disease of the active joint, mainly manifested by a breakdown of articular cartilage matrix, a decrease in chondrocytes, a decrease in activity, etc. The Chinese guidelines for diagnosis and treatment of osteoarthritis report that osteoarthritis has a prevalence of 50% in people over 60 years old and 80% in people over 75 years old, with disability rate of 53%. Therefore, early screening diagnosis and prevention of osteoarthritis are of great significance to improving the quality of life of people.
LncRNAs are a class of RNA molecules with transcripts exceeding 200 nucleotides in length, which do not encode proteins due to the lack of efficient open reading frames, but regulate gene expression at multiple levels, such as epigenetic, transcriptional and post-transcriptional levels, in RNA form, thereby affecting disease development and progression. With the development of high throughput sequencing technologies, more and more LncRNAs are annotated. Therefore, we aimed at looking for effective LncRNA as a marker for clinical diagnosis, treatment and prognostic detection of osteoarthritis, thereby improving the quality of life of osteoarthritis patients.
Disclosure of Invention
The invention provides an LncRNA marker HOXC-AS3 related to osteoarthritis and application thereof, and researches prove that the expression of LncRNA HOXC-AS3 in osteoarthritis articular chondrocytes is obviously lower than that of normal articular chondrocytes. Specifically, reduced expression levels of LncRNA HOXC-AS3 can be used AS a biomarker for diagnosing the occurrence and prognosis of osteoarthritis.
Use of a substance for detecting HOXC-AS3 for the preparation of an assisted diagnosis or prognosis evaluation agent for osteoarthritis. As a preferable aspect of the present invention, the substance for detecting HOXC-AS3 is a primer or probe specific to HOXC-AS 3.
As a further preferred aspect of the present invention, the specific primers for HOXC-AS3 are shown in SEQ ID NO.1 and SEQ ID NO. 2.
An osteoarthritis aiding diagnostic or prognostic assessment agent comprising a substance that detects HOXC-AS 3.
As a preferable aspect of the present invention, the substance for detecting HOXC-AS3 is a primer or probe specific to HOXC-AS 3.
As a further preferred aspect of the present invention, the specific primers for HOXC-AS3 are shown in SEQ ID NO.1 and SEQ ID NO. 2.
Application of HOXC-AS3 or substances for increasing HOXC-AS3 expression level in preparing medicines for treating or adjunctively treating osteoarthritis is provided. The nucleotide sequence of HOXC-AS3 is shown AS SEQ NO. 3.
The beneficial effects are that: the invention discovers that the LncRNA marker HOXC-AS3 related to osteoarthritis has the expression in the articular chondrocytes of osteoarthritis obviously lower than that of corresponding normal articular chondrocytes, and can be used AS an early-stage screening, auxiliary screening diagnosis or prognosis evaluation index of osteoarthritis. The invention finds that compared with a control group, the expression level of HOXC-AS3 is obviously reduced in an OA cell model (figure 5), the proliferation capacity of chondrocytes is reduced after the HOXC-AS3 is knocked down (figure 7), the expression of Edu positive chondrocytes is obviously reduced (figure 8), the chondrocytes are blocked in the G0/G1 phase (figures 9-10), and the clonality forming capacity of the chondrocytes is reduced (figures 11-12); whereas chondrocyte proliferation capacity (FIG. 14) and cell clone formation capacity (FIGS. 15-16) increased after over-expression of OXC-AS 3. As can be seen, HOXC-AS3 can be used AS a molecular marker of OA and applied to preparing a diagnostic kit of OA or become a candidate drug for treating OA.
Drawings
FIG. 1 is a gene sequencing analysis of genes differentially expressed by normal articular chondrocytes and OA chondrocytes.
FIG. 2 shows the detection of LncHOXC-AS3 expression in clinical normal articular chondrocytes and chondrocytes from patients with OA by RT-qPCR.
Fig. 3 is a ROC curve verification graph.
FIG. 4 shows the Western Blot detection of protein expression in normal control and OA chondrocyte model after construction of OA cell model with IL-1. Beta.
FIG. 5 shows the expression of LncRNA HOXC-AS3 in normal control and OA chondrocyte models by RT-qPCR after construction of OA cell models with IL-1. Beta.
FIG. 6 shows the mRNA level expression levels after specific knockdown of HOXC-AS3 with siRNA in human chondrocytes.
FIG. 7 shows cell proliferation following specific knockdown of HOXC-AS3 in chondrocytes.
FIG. 8 shows Edu positive cell expression after specific knockdown of HOXC-AS3 in chondrocytes.
FIG. 9 is a flow chart of cell cycle assays following specific knockdown of HOXC-AS3 in chondrocytes.
FIG. 10 is a flow chart of cell cycle detection statistics after specific knockdown of HOXC-AS3 in chondrocytes.
FIG. 11 shows cell clone formation after specific knockdown of HOXC-AS3 in chondrocytes.
FIG. 12 is a statistical plot of cell clones following specific knockdown of HOXC-AS3 in chondrocytes.
FIG. 13 shows the expression level of mRNA after the human chondrocyte overexpresses HOXC-AS 3.
FIG. 14 shows cell proliferation after overexpression of HOXC-AS3 in chondrocytes.
FIG. 15 shows cell clone formation after overexpression of HOXC-AS3 in chondrocytes.
FIG. 16 is a statistical plot of cell clones after overexpression of HOXC-AS3 in chondrocytes.
Detailed Description
Example 1 clinical sample analysis
The clinical samples adopted by the invention are all from a first hospital in Nanjing city. The project solicits consent from the patient and is approved by the ethical committee of the university of south Beijing medical science.
(1) Tissue specimen source and collection
Cartilage specimens were from patients receiving knee arthroplasty or hip arthroplasty at first hospital in Nanjing, 2019 through 2021. Of these, 16 patients who underwent hip replacement due to femoral neck fracture were included in the normal control group. An additional 16 cases were included in the OA group due to severe knee osteoarthritis and knee arthroplasty.
After the tissue of the sample is isolated in the operation, the tissue is placed in a sterile 50mL centrifuge tube under the sterile condition, and then immediately placed in liquid nitrogen for quick freezing, and then stored in a refrigerator at the temperature of minus 80 ℃ for subsequent use in gene sequencing or gene sequencing.
(2) Gene sequencing and data analysis
We sent 5 pairs of normal control samples and OA samples harvested in clinical surgery to the shanghai-sky biotechnology company for lncRNAs sequencing analysis and annotated differentially expressed lncRNAs (see figure 1 for results). (3) Real-time PCR
a) Total chondrocyte RNA extraction: trizol method extracts total RNA from normal control chondrocytes and OA chondrocytes. Mu.l Trizol was added. 100ul of chloroform was added, and the mixture was vigorously shaken to mix the upper and lower phases thoroughly, and after 10 minutes of standing at room temperature, the mixture was centrifuged at 12000Xg for 15 minutes at 4 ℃. The upper aqueous phase was carefully aspirated 160ul into a fresh RNase free EP tube, an equal volume of isopropanol (160 ul) was added, mixed upside down, and after 20min on ice, centrifuged at 12000Xg for 15min at 4℃and the white RNA pellet was seen in the tube after centrifugation. The supernatant was discarded, and the pellet was washed once with pre-chilled 75% ethanol (DEPC water dilution), 70000 g and centrifuged at 5min at 4 ℃. Discarding the supernatant, standing at room temperature, and airing (10-15 min) to volatilize the alcohol completely. Then, 15. Mu.l of DEPC water was added for dissolution and the concentration was measured for later use.
b) RNA inversion into cDNA: RNA reverse transcription was performed using reverse transcription kit (genome DNA removal) from Nanjinopran (vazyme) company according to the kit instructions, the reverse transcription system being as follows:
reagent(s) Dosage of
RNA 1μg
4×gDNA wiper Mix 4μl
RNase free ddH 2 O To 16 μl
Mixing the above mixture, reacting at 42 ℃ for 2min by a PCR instrument, and continuing the second step of reversion:
reagent(s) Dosage of
The above mixture 16μl
5×HiScriptⅡqRT SuperMixⅡ 4μl
After mixing, reverse transcription PCR was performed under the following conditions: 50 ℃ for 15min; the cDNA product obtained at 85℃for 5s can be used for Real-time PCR
c) Real-time PCR: real-time PCR was performed using the cDNA of the previous step as a template, and was performed using SYBR Green Mix from Novazyme (Vazyme) according to the kit instructions. 10 μl system:
Figure BDA0003810312030000041
after the above mixture was mixed, real-time PCR was performed under the following reaction conditions: 95 ℃ for 5min;95 ℃,10s-60 ℃ and 30s;40 cycles
The primer sequences were as follows:
Primers Sequence(5’-3’)
β-actin-F TCATGAAGTGTGACGTGGACAT
β-actin-R CTCAGGAGGAGCAATGATCTTG
HOXC-AS3-F GTGGAGTAACAGCGCCATCT
HOXC-AS3-R CGGGTTTTGTTGCGTCTTGT
d) Results: the invention detects the expression level of HOXC-AS3 in the clinical OA cartilage and normal control cartilage cells by using Real-time PCR technology, and discovers that the expression level of HOXC-AS3 is obviously reduced in the OA cartilage cells (the result is shown in figure 2).
(4) ROC Curve verification
ROC curve verification was performed on 5 pairs of OA group and control group HOXC-AS3 expression level differences using pROC, an R package. The cut-off value of the predictive variable HOXC-AS3 is 5.568, the positive predictive value and the negative predictive value are both 1, the about sign index is 1, the AUC of the predictive outcome of the control group and the OA group by using the HOXC-AS3 is 1, the confidence interval is 1.000-1.000, and the result proves that the selected index has high accuracy in predicting the outcome (the result is shown in figure 3).
Example 2OA cell model experiment
Human chondrocyte cell line C28/I2 was purchased from Shanghai Yu Biotech Co.
(1) Cell culture
A sample containing 10% of fetal bovine serum (Gibco), 1% triple antibody (i.e., 100U/mL penicillin, 100mg/mL streptomycin, and 25. Mu.g/mL amphotericin B) (Gibco) in DMEM medium (Gibco) containing 5% CO at 37 ℃C 2 C28/I2 cell culture was performed in a sterile incubator with medium change every 2-3 days, when cells were 80% -90% fused, pancreatin digested to 1:2 or 1: 3.
(2) Construction of OA cell model
C28/I2 cells were cultured in DMEM medium containing IL-1β (Sigma) at 10ng/ml or 20ng/ml for 24 hours, and OA cell models were constructed, and untreated cells were used as a control group.
(3)Western Blot
a) Total cell protein extraction
Adding 200 μl RIPA containing 10% PI and 10% PMSF into the adherent cells, shaking the culture plate lightly to make the cells fully contacted with liquid, shaking on ice for 5min, scraping the cells in the culture plate from the bottom of the plate by using a clean and sterile cell scraper, transferring the cells into a sterile and enzyme-free 1.5mL EP tube, placing the EP tube on ice obliquely, incubating under shaking for 15-20min to completely lyse the sample, and centrifuging at 4 ℃ for 10min; sucking the supernatant into a new EP pipe, and temporarily storing on ice;
according to the specification of the Biyundian BCA protein concentration determination kit, the protein concentration is determined by ddH 2 O the sample protein was diluted to 300. Mu.g/80. Mu.l and 20. Mu.l of 5-x loading buffer was added, and the metal bath was kept at 100deg.C for 10min.
Cooling at room temperature;
b) Preparing 10% separating gel and concentrating gel
Reagent(s) Release adhesive (mu l) Concentrated glue (mu l)
ddH 2 O 1900 680
30% AA solution 1700 166
1MTris-HCl(pH=8.8) 1300 \
1M Tris-HCl(pH=6.8) \ 126
10%SDS 50 10
10%APS 50 10
TEMED 4 1
c) Preparing SDS-PAGE gel, firstly pouring the prepared separating gel into a glass plate, preventing and treating bubbles, slowly adding ddH to a position 1.5cm away from the upper edge of the glass plate 2 O pressing the gel to isolate air, standing for about 30min until the gel surface and the water phase have obvious interface, namely separating gel to solidify, pouring out upper liquid, preparing upper concentrated gel, adding a glass plate, immediately inserting a comb, and standing for solidification;
d) Mounting the gel plate in an electrophoresis tank, pouring 1x electrophoresis liquid into the inner tank and the outer tank, adding sample by a sample loading gun, starting electrophoresis at a constant voltage of 80V until a marker is separated, and adjusting the voltage to 110V until the electrophoresis is completed;
e) After electrophoresis, the gel was taken out and put in ddH 2 In O, placing the PVDF membrane in methanol for activating for 30s, and transferring to pre-cooled membrane transferring liquid; putting sponge and filter paper in a film transfer clamp plate, putting gel and PVDF film in the current direction (from black to red), putting the gel on one side of a black plate, discharging bubbles between each layer by light pressure, closing the clamp plate, putting the film transfer clamp plate into a film transfer groove, putting the gel surface (black side) facing the negative electrode of the film transfer groove, putting the PVDF film facing the positive electrode, pouring precooling film transfer liquid, putting an ice box, putting the film transfer groove into a refrigerator at 4 ℃, keeping the film transfer at low temperature, and transferring the film at constant current of 0.28A for 90min;
f) After the transfer, taking out PVDF film and ddH 2 And O is washed twice, ponceau is put into the membrane for dyeing, whether protein bands exist or not is observed, and whether membrane transfer is successful or not is judged. After washing ponceau, sealing with 5% milk-TBST, and standing for 2h at room temperature;
g) Placing the blocked membrane into an antibody incubation box, adding a primary antibody diluted with 5% BSA/TBST according to the ratio of 1:10000, and standing overnight at 4 ℃;
h) The next day, the membrane is washed by TBST, and the membrane is washed by a shaking table for 3 times, each time for 5min; adding the diluted secondary antibody 1:10000, and incubating for 2 hours at room temperature;
i) TBST is used for washing the membrane for three times, each time for 5min;
j) Preparing ECL developing solution, placing the film, performing exposure imaging with a chemiluminescent imaging system, photographing and archiving;
results: western Blot experiments showed (see FIG. 4 for results) that we successfully constructed OA chondrocyte models using either 10ng/ml or 20ng/ml IL-1β.
(4)Real-time PCR
a) Total cell RNA extraction: the Trizol method extracts cellular RNA. Mu.l Trizol was added. 100ul of chloroform was added, and the mixture was vigorously shaken to mix the upper and lower phases thoroughly, and after 10min of standing on ice, the mixture was centrifuged at 12000Xg for 15min at 4 ℃. The upper aqueous phase was carefully aspirated 160ul into a fresh RNase free EP tube, an equal volume of isopropanol (160 ul) was added, mixed upside down, and after 10min at room temperature, centrifuged at 12000Xg for 15min at 4℃and the white RNA pellet was seen in the tube after centrifugation. The supernatant was discarded, and the pellet was washed once with pre-chilled 75% ethanol (DEPC water dilution), 70000 g and centrifuged at 5min at 4 ℃. Discarding the supernatant, standing at room temperature, and airing (10-15 min) to volatilize the alcohol completely. Then, 15. Mu.l of DEPC water was added for dissolution and the concentration was measured for later use.
b) RNA inversion into cDNA: RNA reverse transcription was performed using reverse transcription kit (genome DNA removal) from Nanjinopran (vazyme) company according to the kit instructions, the reverse transcription system being as follows:
reagent(s) Dosage of
RNA 1μg
4×gDNA wiper Mix 4μl
RNase free ddH 2 O To 16 μl
Mixing the above mixture, reacting at 42 ℃ for 2min by a PCR instrument, and continuing the second step of reversion:
reagent(s) Dosage of
The above mixture 16μl
5×HiScriptⅡqRT SuperMixⅡ 4μl
After mixing, reverse transcription PCR was performed under the following conditions: 50 ℃ for 15min; the cDNA product obtained at 85℃for 5s can be used for Real-time PCR
c) Real-time PCR: real-time PCR was performed using the cDNA of the previous step as a template, and was performed using SYBR Green Mix from Novazyme (Vazyme) according to the kit instructions. 10 μl system:
Figure BDA0003810312030000081
after the above mixture was mixed, real-time PCR was performed under the following reaction conditions: 95 ℃ for 5min;95 ℃,10s-60 ℃ and 30s;40 cycles
The primer sequences were as follows:
Primers Sequence(5’-3’)
β-actin-F TCATGAAGTGTGACGTGGACAT
β-actin-R CTCAGGAGGAGCAATGATCTTG
HOXC-AS3-F GTGGAGTAACAGCGCCATCT
HOXC-AS3-R CGGGTTTTGTTGCGTCTTGT
d) Results: real-time PCR results showed that HOXC-AS3 expression levels were significantly reduced in OA cell models compared to control (see fig. 5 for results).
Example 3 specific knockdown of HOXC-AS3 effect on chondrocyte proliferation and clonogenic Capacity
(1) Specific knockdown of HOXC-AS3
The HOXC-AS3 was knocked down in human chondrocyte line C28/I2 with small interfering RNA (siRNA), and the knockdown efficiency was detected AS follows:
the r.p. RiboBio (libo) company was designed to synthesize small interfering RNAs (sirnas). The sequence is as follows:
name of the name Target sequence
si-HOXC-AS3 1# CAGAGUGGAGUAACAGCGCCAUCUA
si-HOXC-AS3 2# CGGUCAGUUUGGAGGAGUCACGUAU
Seed 1x10 in six well plates 5 Cells were transfected with 5. Mu.l of transfection reagent Lipofectamine 3000 (Invitrogen) plus 100pmol of siRNA per well after attachment, and harvested after 48 h.
(2)Real-time PCR
a) Total cell RNA extraction: triRNA was extracted by zol method. Collect about 1X10 6 Mu.l Trizol was added to each cell. 100ul of chloroform was added, and the mixture was vigorously shaken to mix the upper and lower phases thoroughly, and after 10min of standing on ice, the mixture was centrifuged at 12000Xg for 15min at 4 ℃. The upper aqueous phase was carefully aspirated 160ul into a fresh RNase free EP tube, an equal volume of isopropanol (160 ul) was added, mixed upside down, and after 10min at room temperature, centrifuged at 12000Xg for 15min at 4℃and the white RNA pellet was seen in the tube after centrifugation. The supernatant was discarded, and the pellet was washed once with pre-chilled 75% ethanol (DEPC water dilution), 70000 g and centrifuged at 5min at 4 ℃. Discarding the supernatant, standing at room temperature, and airing (10-15 min) to volatilize the alcohol completely. Then, 15. Mu.l of DEPC water was added for dissolution and the concentration was measured for later use.
b) RNA inversion into cDNA: RNA reverse transcription was performed using reverse transcription kit (genome DNA removal) from Nanjinopran (vazyme) company according to the kit instructions, the reverse transcription system being as follows:
reagent(s) Dosage of
RNA 1μg
4×gDNA wiper Mix 4μl
RNase free ddH 2 O To 16 μl
Mixing the above mixture, reacting at 42 ℃ for 2min by a PCR instrument, and continuing the second step of reversion:
reagent(s) Dosage of
The above mixture 16μl
5×HiScriptⅡqRT SuperMixⅡ 4μl
After mixing, reverse transcription PCR was performed under the following conditions: 50 ℃ for 15min; the cDNA product obtained at 85℃for 5s can be used for Real-time PCR
c) Real-time PCR: real-time PCR was performed using the cDNA of the previous step as a template, and was performed using SYBR Green Mix from Novazyme (Vazyme) according to the kit instructions. 10 μl system:
reagent(s) Dosage of
cDNA 1μl
H 2 O 3.6μl
Upstream primer 0.2μl
Downstream primer 0.2μl
SYBR Green Mix 5μl
After the above mixture was mixed, real-time PCR was performed under the following reaction conditions: 95 ℃ for 5min;95 ℃,10s-60 ℃ and 30s;40 cycles
The primer sequences were as follows:
Primers Sequence(5’-3’)
β-actin-F TCATGAAGTGTGACGTGGACAT
β-actin-R CTCAGGAGGAGCAATGATCTTG
HOXC-AS3-F GTGGAGTAACAGCGCCATCT
HOXC-AS3-R CGGGTTTTGTTGCGTCTTGT
d) Results: real-time PCR results showed that expression of HOXC-AS3 in human chondrocytes could be effectively knocked down using small interfering RNAs (see figure 6 for results).
(3) Cell proliferation potency assay-MTT
a) Respectively inoculating cartilage cells transfected with si-NC and si-HOXC-AS3 into 96-well plates according to the number of 3000 cells/well, and placing the cartilage cells into a cell culture box for more than 8 hours until the cells adhere to the walls; adding 20 mu L MTT reagent into each hole, and continuously culturing in an incubator for 4 hours; detecting absorbance at 490nm by using an enzyme-labeled instrument as a growth degree of 0h, and performing the same operation every 24 hours until 96 hours; fold increase indicates cell proliferation capacity by comparison with 0h absorbance.
b) Results: chondrocyte proliferation was decreased upon knockout of HOXC-AS3 (see figure 7 for results).
(4) Cell proliferation potency assay-Edu cell immunofluorescence
a) Cells were counted 24h after transfection at 2X 10 4 Individual cells/wells were seeded into 24-well plates containing cell slide;
b) Removing the culture medium when the cells are fused to 60% -70%, preparing 50 mu M EdU culture medium according to a ratio of 1:1000, adding 300 mu L of the EdU culture medium into each hole, incubating for 3h, and washing with PBS for 5min each time;
c) 500 mu L of PBS containing 4% paraformaldehyde is added into each hole, the mixture is incubated for 30min at room temperature, and the fixing solution is sucked off;
d) Adding 300 mu L glycine (2 mg/mL) into each hole, and incubating for 5min by a shaking table, and sucking out glycine solution;
e) Adding 500 μl of PBS into each well, washing with shaking table for 5min, and discarding;
f) 300 mu L of 0.5% TritonX-100 PBS is added to each well, the mixture is incubated for 10min by a shaker, and the mixture is washed for 5min by PBS;
g) Preparing 1 XApollo staining reaction liquid according to the specification, adding 300 mu L of the Apollo staining liquid into each hole, incubating for 30min at room temperature in a dark place, and absorbing and removing the staining liquid;
h) 300 mu L of 0.5% TritonX-100 PBS is added to each well, and the mixture is incubated for 3 times by a shaker for 10min each time;
i) Adding 300 mu L of methanol into each hole for cleaning for 3 times, and cleaning for 5min in PBS (phosphate buffered saline);
j) Deionized water was used according to 1:100 preparing 1 Xhoechst 33342 reaction liquid, adding 300 mu L of 1 Xhoechst 33342 reaction liquid into each hole, and incubating for 30min at room temperature in a dark place;
k) Adding 500 mu L of PBS into each hole, and cleaning for 3 times; photographs were taken using a fluorescence microscope, and the positive spot ratio was counted.
l) results: edu positive chondrocyte expression was significantly reduced upon knockout of HOXC-AS3 (see figure 8 for results).
(5) Cell cycle detection
a) Collecting cells, washing with pre-chilled PBS;
b) Fixing with pre-cooled 75% ethanol at-20deg.C overnight;
c) Centrifugation at 1500Xg for 5min at 4℃and removal of supernatant, re-suspension of each sample with 450. Mu.L PBS; d) Cells were stained with 50 μl PI in the dark for 15min at room temperature;
e) FACS Calibur flow cytometer (BD) cell cycle flow detection and analysis;
f) Results: after knocking down HOXC-AS3, chondrocytes were arrested in the G0/G1 phase (see FIGS. 9-10 for results).
(6) Cloning formation experiments
a) The cells transfected with si-NC and si-HOXC-AS for 3 hours are digested and inoculated into a six-hole plate in the quantity of 500 cells/hole, and a culture plate is gently shaken to evenly spread the cells and put into an incubator for culture;
b) Every 3 days, the new medium was changed until colony formation was visible to the naked eye on day 10;
c) Discarding the culture medium, washing twice with PBS, adding 1ml paraformaldehyde, standing and fixing for 15min;
d) Sucking off paraformaldehyde and adding ddH 2 O washing for 3 times, each time for 2min;
e) Adding 1ml of 1-crystal violet reagent, standing in dark, dyeing for 15min, and then using ddH 2 O is washed for a plurality of times until excessive crystal violet is washed and dried;
f) And taking pictures by a camera, and counting the number of clones.
g) Results: upon knocking down HOXC-AS3, the chondrocyte clonogenic capacity was reduced (see fig. 11-12 for the results).
Example 4 Effect of over-expression of HOXC-AS3 on chondrocyte proliferation and clonogenic Capacity
(1) Overexpression of HOXC-AS3
Over-expression of HOXC-AS3 by transfection plasmid in human cartilage cell C28/I2 and detection thereofThe expression efficiency comprises the following specific steps: seed 1x10 in six well plates 5 Cells were transfected with the transfection complex of the transfection reagent X-tremeGENE DNA Transfection Reagent. Mu.l+4. Mu.g plasmid per well after adherence, and after 48h, the cells were harvested and RNA was extracted.
(2)Real-time PCR
a) Total cell RNA extraction: RNA was extracted by Trizol method. Collect about 1X10 6 Mu.l Trizol was added to each cell/group. 100ul of chloroform was added, and the mixture was vigorously shaken to mix the upper and lower phases thoroughly, and after 10min of standing on ice, the mixture was centrifuged at 12000Xg for 15min at 4 ℃. The upper aqueous phase was carefully aspirated 160ul into a fresh RNase free EP tube, an equal volume of isopropanol (160 ul) was added, mixed upside down, and after 10min at room temperature, centrifuged at 12000Xg for 15min at 4℃and the white RNA pellet was seen in the tube after centrifugation. The supernatant was discarded, and the pellet was washed once with pre-chilled 75% ethanol (DEPC water dilution), 70000 g and centrifuged at 5min at 4 ℃. Discarding the supernatant, standing at room temperature, and airing (10-15 min) to volatilize the alcohol completely. Then, 15. Mu.l of DEPC water was added for dissolution and the concentration was measured for later use.
b) RNA inversion into cDNA: RNA reverse transcription was performed using reverse transcription kit (genome DNA removal) from Nanjinopran (vazyme) company according to the kit instructions, the reverse transcription system being as follows:
reagent(s) Dosage of
RNA 1μg
4×gDNA wiper Mix 4μl
RNase free ddH 2 O To 16 μl
Mixing the above mixture, reacting at 42 ℃ for 2min by a PCR instrument, and continuing the second step of reversion:
reagent(s) Dosage of
The above mixture 16μl
5×HiScriptⅡqRT SuperMixⅡ 4μl
After mixing, reverse transcription PCR was performed under the following conditions: 50 ℃ for 15min; the cDNA product obtained at 85℃for 5s can be used for Real-time PCR
c) Real-time PCR: real-time PCR was performed using the cDNA of the previous step as a template, and was performed using SYBR Green Mix from Novazyme (Vazyme) according to the kit instructions. 10 μl system:
reagent(s) Dosage of
cDNA 1μl
H 2 O 3.6μl
Upstream primer 0.2μl
Downstream primer 0.2μl
SYBR Green Mix 5μl
After the above mixture was mixed, real-time PCR was performed under the following reaction conditions: 95 ℃ for 5min;95 ℃,10s-60 ℃ and 30s;40 cycles
The primer sequences were as follows:
Primers Sequence(5’-3’)
β-actin-F TCATGAAGTGTGACGTGGACAT
β-actin-R CTCAGGAGGAGCAATGATCTTG
HOXC-AS3-F GTGGAGTAACAGCGCCATCT
HOXC-AS3-R CGGGTTTTGTTGCGTCTTGT
d) Results: the Real-time PCR results showed a significant increase in expression of HOXC-AS3 in human chondrocytes (see fig. 13 for results).
(3) Cell proliferation potency assay-MTT
a) Respectively inoculating chondrocytes of an NC group, an IL-1β group, an IL-1β+empty vector group and an IL-1β+HOXC-AS3 group into 96-well plates according to the number of 3000 cells/well, and placing the cells into a cell incubator for more than 8 hours until the cells adhere to the wall; adding 20 mu L MTT reagent into each hole, and continuously culturing in an incubator for 4 hours; detecting absorbance at 490nm by using an enzyme-labeled instrument as a growth degree of 0h, and performing the same operation every 24 hours until 96 hours; fold increase indicates cell proliferation capacity by comparison with 0h absorbance.
b) Results: after overexpression of HOXC-AS3, chondrocyte proliferation capacity was significantly increased (see figure 14 for results).
(4) Cloning formation experiments
a) The method comprises the steps of (1) inoculating chondrocytes of an NC group, an IL-1 beta group, an IL-1 beta+empty vector group and an IL-1 beta+HOXC-AS 3 group into a six-hole plate in the number of 500 cells/hole after digestion, and putting the cells into an incubator for culture by shaking the culture plate slightly to uniformly spread the cells;
b) Every 3 days, the new medium was changed until colony formation was visible to the naked eye on day 10;
c) Discarding the culture medium, washing twice with PBS, adding 1ml paraformaldehyde, standing and fixing for 15min;
d) Sucking off paraformaldehyde and adding ddH 2 O washing for 3 times, each time for 2min;
e) Adding 1ml of 1-crystal violet reagent, standing in dark, dyeing for 15min, and then using ddH 2 O is washed for a plurality of times until excessive crystal violet is washed and dried;
f) And taking pictures by a camera, and counting the number of clones.
g) Results: after overexpression of HOXC-AS3, chondrocyte clonality was increased (see fig. 15-16 for results).
By combining clinical samples and in vitro cell experiments, it can be found that the expression of HOXC-AS3 in OA is significantly lower than that of normal control. The expression of the HOXC-AS3 of the cartilage cells is knocked down, so that the proliferation of the cartilage cells can be inhibited, and the cloning capacity of the cartilage cells is reduced; and the over-expression of HOXC-AS3 can promote the proliferation of chondrocytes and increase the clonogenic capacity of the chondrocytes. The HOXC-AS3 can be used AS a molecular marker of OA and applied to preparing diagnostic kits of OA.
In the foregoing, the protection scope of the present invention is not limited to the preferred embodiments of the present invention, and any simple changes or equivalent substitutions of the technical solutions that can be obviously obtained by those skilled in the art within the technical scope of the present invention disclosed in the present invention fall within the protection scope of the present invention.

Claims (7)

1. Use of a substance for detecting HOXC-AS3 for the preparation of an assisted diagnosis or prognosis evaluation agent for osteoarthritis.
2. The use according to claim 1, characterized in that the substance for detecting HOXC-AS3 is a primer, probe specific for HOXC-AS 3.
3. The use according to claim 1, characterized in that the specific primers for HOXC-AS3 are shown in SEQ ID No.1 and SEQ ID No. 2.
4. An osteoarthritis auxiliary diagnostic or prognostic assessment agent, characterized in that it comprises a substance for detecting HOXC-AS 3.
5. The osteoarthritis auxiliary diagnostic or prognostic assessment reagent according to claim 4, wherein the substance for detecting HOXC-AS3 is a primer or probe specific to HOXC-AS 3.
6. The osteoarthritis auxiliary diagnostic or prognostic assessment agent according to claim 5, wherein the specific primer of HOXC-AS3 is shown in SEQ ID No.1 and SEQ ID No. 2.
Application of HOXC-AS3 or substances for increasing HOXC-AS3 expression amount in preparing medicines for treating or adjunctively treating osteoarthritis is provided.
CN202211009871.0A 2022-08-23 2022-08-23 LncRNA marker related to osteoarthritis and application thereof Active CN116064767B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211009871.0A CN116064767B (en) 2022-08-23 2022-08-23 LncRNA marker related to osteoarthritis and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211009871.0A CN116064767B (en) 2022-08-23 2022-08-23 LncRNA marker related to osteoarthritis and application thereof

Publications (2)

Publication Number Publication Date
CN116064767A true CN116064767A (en) 2023-05-05
CN116064767B CN116064767B (en) 2024-06-04

Family

ID=86175742

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211009871.0A Active CN116064767B (en) 2022-08-23 2022-08-23 LncRNA marker related to osteoarthritis and application thereof

Country Status (1)

Country Link
CN (1) CN116064767B (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101433600A (en) * 2008-08-22 2009-05-20 中山大学 Chinese medicinal composition for treating ostarthritis and preparation method thereof
CN104971086A (en) * 2014-04-09 2015-10-14 台北医学大学 Application of uraria for promoting osteogenesis or providing neuro-protection
WO2018009838A1 (en) * 2016-07-07 2018-01-11 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems expressing exogenous rna
WO2018111944A1 (en) * 2016-12-12 2018-06-21 Whitehead Institute For Biomedical Research Regulation of transcription through ctcf loop anchors
CN109925507A (en) * 2017-12-15 2019-06-25 深圳瑞健生命科学研究院有限公司 A kind of method and drug prevented or treat osteoarthritis
US20190338244A1 (en) * 2017-11-30 2019-11-07 New York Medical College Multipotent adult stem cells: characterization and use
CN113249464A (en) * 2021-04-13 2021-08-13 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) Use of circular RNA as osteoarthritis marker

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101433600A (en) * 2008-08-22 2009-05-20 中山大学 Chinese medicinal composition for treating ostarthritis and preparation method thereof
CN104971086A (en) * 2014-04-09 2015-10-14 台北医学大学 Application of uraria for promoting osteogenesis or providing neuro-protection
WO2018009838A1 (en) * 2016-07-07 2018-01-11 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems expressing exogenous rna
WO2018111944A1 (en) * 2016-12-12 2018-06-21 Whitehead Institute For Biomedical Research Regulation of transcription through ctcf loop anchors
US20190338244A1 (en) * 2017-11-30 2019-11-07 New York Medical College Multipotent adult stem cells: characterization and use
CN109925507A (en) * 2017-12-15 2019-06-25 深圳瑞健生命科学研究院有限公司 A kind of method and drug prevented or treat osteoarthritis
CN113249464A (en) * 2021-04-13 2021-08-13 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) Use of circular RNA as osteoarthritis marker

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HONG SUN等: "Emerging roles of long noncoding RNA in chondrogenesis, osteogenesis, and osteoarthritis", AM J TRANSL RES, vol. 11, 15 January 2019 (2019-01-15), pages 16 - 30 *
余杨洋等: "LncRNA调控各类细胞成骨分化的机制研究进展", 安徽医科大学学报, no. 04, 31 December 2020 (2020-12-31), pages 647 - 652 *
佚名: "NR_047506.1", NCBI, 24 July 2022 (2022-07-24), pages 1 - 2 *
李润泽等: "长链非编码RNA调控成骨分化的研究现状及展望", 中华口腔医学研究杂志(电子版), no. 05, 31 October 2020 (2020-10-31), pages 271 - 279 *
李萍等: "lncRNA HOXB-AS3靶向miR-379-5p调节类风湿性关节炎滑膜成纤维细胞增殖、迁移和侵袭的机制研究", 河北医药, vol. 43, 10 June 2021 (2021-06-10), pages 1616 - 1620 *

Also Published As

Publication number Publication date
CN116064767B (en) 2024-06-04

Similar Documents

Publication Publication Date Title
CN111718995B (en) Biomarker for nasopharyngeal carcinoma metastasis diagnosis and/or prognosis evaluation
CN116004822B (en) PCR kit for breast cancer diagnosis
CN111743912B (en) Gene inhibitor for promoting colon cancer cell apoptosis and inhibiting colon cancer cell migration
CN116064767B (en) LncRNA marker related to osteoarthritis and application thereof
CN113278696B (en) Molecular marker RAD51B-AS1 and application thereof
CN115252637B (en) Gene inhibitor with liver cancer metastasis inhibiting function
CN109852692B (en) circ _3480, application thereof in preparation of nasopharyngeal carcinoma diagnostic preparation and diagnostic reagent
CN115851940A (en) Osteosarcoma molecular marker and application thereof
CN114002431A (en) Application of TNNT1 in preparation of virus-type hepatocellular carcinoma diagnostic kit and preparation or screening of anti-liver cancer drugs
CN115837079A (en) Application of IGF2BP1 high expression in esophageal cancer detection and treatment
CN113652429A (en) shRNA for targeted knockdown of long-chain non-coding RNAMIR205HG and application thereof
CN116637123B (en) Application of reagent for knocking down or down expression of C15orf39 gene in preparation of medicines for treating gastric cancer
CN111979319A (en) Biomarker for nasopharyngeal carcinoma metastasis diagnosis and/or prognosis evaluation
CN112877425A (en) Application of reagent for detecting SNF5 gene expression in preparation of atherosclerosis diagnosis product
CN114561469B (en) ER positive breast cancer molecular marker and application thereof
CN113337607B (en) Molecular marker for detecting or evaluating curative effect of liver cancer and application
CN109847064B (en) Application of circ _3480 in preparation of nasopharyngeal carcinoma treatment preparation and treatment preparation
CN114410589B (en) Application of ETV4 gene in reprogramming Cheng Zeng-derived scar fibroblast
CN111118154B (en) Application of LINC01272 in preparation of tumor detection reagent and/or treatment drug
CN114908172B (en) Application of APOBEC3B in diagnosis, prognosis prediction and treatment of prostate cancer
CN111848773B (en) Molecular marker RANBP1 related to human colorectal cancer and application thereof
CN111321147B (en) Application of gene inhibitor in preparation of anti-gastric cancer metastasis preparation
WO2024050860A1 (en) Diagnosis reagent for phyllodes tumor and use thereof
CN109880828B (en) siRNA for interfering Mroh7 gene expression and application, interference method and medicament thereof
CN116492470A (en) Application of miR-148a-5p in treatment of diabetic nephropathy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant